MedTrace Logo

Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

NCT04539301 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2100

Last updated 2024-05-07

No results posted yet for this study

Summary

Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.

Conditions

Interventions

DIAGNOSTIC_TEST

Estimated anticoagulant level (conversion factor x anti-Xa activity)

Estimated anticoagulant level (conversion factor x anti-Xa activity)

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04539301 on ClinicalTrials.gov